Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.
2.

Stereotactic ablative body radiotherapy for lung cancer.

Franks KN, Jain P, Snee MP.

Clin Oncol (R Coll Radiol). 2015 May;27(5):280-9. doi: 10.1016/j.clon.2015.01.006. Epub 2015 Mar 4.

PMID:
25746732
3.

Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?

Widder J, Klinkenberg TJ, Ubbels JF, Wiegman EM, Groen HJ, Langendijk JA.

Radiother Oncol. 2013 Jun;107(3):409-13. doi: 10.1016/j.radonc.2013.05.024. Epub 2013 Jun 14.

PMID:
23773410
4.

Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.

Iyengar P, Westover K, Timmerman RD.

Semin Respir Crit Care Med. 2013 Dec;34(6):845-54. doi: 10.1055/s-0033-1358554. Epub 2013 Nov 20. Review.

PMID:
24258574
5.

Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.

Chang JY, Liu YH, Zhu Z, Welsh JW, Gomez DR, Komaki R, Roth JA, Swisher SG.

Cancer. 2013 Sep 15;119(18):3402-10. doi: 10.1002/cncr.28217. Epub 2013 Jun 24.

6.

Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?

Bilal H, Mahmood S, Rajashanker B, Shah R.

Interact Cardiovasc Thorac Surg. 2012 Aug;15(2):258-65. doi: 10.1093/icvts/ivs179. Epub 2012 May 10. Review.

7.

Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction.

Musunuru HB, Loblaw A.

Future Oncol. 2015;11(5):819-31. doi: 10.2217/fon.15.14. Review.

PMID:
25757684
8.

To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.

Shultz DB, Diehn M, Loo BW Jr.

Semin Radiat Oncol. 2015 Apr;25(2):78-86. doi: 10.1016/j.semradonc.2014.11.005. Epub 2014 Nov 25. Review.

PMID:
25771411
9.
10.

CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy.

Sawyer B, Pun E, Samuel M, Tay H, Kron T, Bressel M, Ball D, Siva S.

J Med Imaging Radiat Oncol. 2015 Apr;59(2):207-15. doi: 10.1111/1754-9485.12272. Epub 2015 Jan 20.

PMID:
25601133
11.

Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.

Shultz DB, Filippi AR, Thariat J, Mornex F, Loo BW Jr, Ricardi U.

J Thorac Oncol. 2014 Oct;9(10):1426-33. doi: 10.1097/JTO.0000000000000317. Review.

12.

Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.

Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):348-53. doi: 10.1016/j.ijrobp.2011.06.2003. Epub 2011 Nov 19.

PMID:
22104360
13.

Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.

Murray L, Ramasamy S, Lilley J, Snee M, Clarke K, Musunuru HB, Needham A, Turner R, Sangha V, Flatley M, Franks K.

Clin Oncol (R Coll Radiol). 2016 Jan;28(1):4-12. doi: 10.1016/j.clon.2015.09.007. Epub 2015 Oct 21.

PMID:
26474546
14.

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II).

Siva S, Kron T, Bressel M, Haas M, Mai T, Vinod S, Sasso G, Wong W, Le H, Eade T, Hardcastle N, Chesson B, Pham D, Høyer M, Montgomery R, Ball D.

BMC Cancer. 2016 Mar 4;16:183. doi: 10.1186/s12885-016-2227-z.

15.

Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.

Senthi S, Haasbeek CJ, Slotman BJ, Senan S.

Radiother Oncol. 2013 Mar;106(3):276-82. doi: 10.1016/j.radonc.2013.01.004. Epub 2013 Feb 22. Review. Erratum in: Radiother Oncol. 2013 Oct;109(1):183. Dosage error in article text.

16.

A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.

Chiang A, Thibault I, Warner A, Rodrigues G, Palma D, Soliman H, Jain S, Poon I, Cheung P.

Radiother Oncol. 2016 Mar;118(3):478-84. doi: 10.1016/j.radonc.2015.12.026. Epub 2016 Jan 18.

PMID:
26795773
17.

Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.

Filippi AR, Badellino S, Guarneri A, Levis M, Botticella A, Mantovani C, Ragona R, Racca P, Buffoni L, Novello S, Ricardi U.

Technol Cancer Res Treat. 2014 Feb;13(1):37-45. doi: 10.7785/tcrt.2012.500355. Epub 2013 Jun 24.

PMID:
23819496
18.

Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.

Boily G, Filion É, Rakovich G, Kopek N, Tremblay L, Samson B, Goulet S, Roy I; Comité de l’évolution des pratiques en oncologie.

J Thorac Oncol. 2015 Jun;10(6):872-82. doi: 10.1097/JTO.0000000000000524. Review.

19.

Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.

Soldà F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M.

Radiother Oncol. 2013 Oct;109(1):1-7. doi: 10.1016/j.radonc.2013.09.006. Epub 2013 Oct 12. Review.

20.

Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.

Hadziahmetovic M, Loo BW, Timmerman RD, Mayr NA, Wang JZ, Huang Z, Grecula JC, Lo SS.

Discov Med. 2010 May;9(48):411-7. Review.

Supplemental Content

Support Center